Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
skip to main content

Long term Use of Peanut Patch Shows Increased Benefit Over Time


AAAAI News Release

February 10, 2025

Contact:
Candace Archie, Communications & Public Relations Manager
carchie@aaaai.org
(414) 272-6071

73% of participants using VIASKIN® peanut patch responded well to treatment

 
Milwaukee, WI – VIASKIN® peanut patch is a well-tolerated treatment for children with peanut allergies according to research being presented at the 2025 AAAAI / WAO Joint Congress.
 
“I am pleased with the long-term results generated from the PEOPLE open-label extension study with the VIASKIN® peanut patch. It is promising that more than 73% of participants were treatment responders, especially in an adolescent patient population, with two-thirds consuming 3-4 peanuts at month 60. We know that VIASKIN® peanut patch is a well-tolerated product with a promising safety profile, which is further supported by an average treatment compliance of 93% of participants up to 5 years. In line with other allergen immunotherapies, these data show that increased benefit is achieved over time,” said lead author David M. Fleischer, MD, FAAAAI.  
 
Previous results from PEOPLE (PEPITES Open-Label Extension) study demonstrated daily treatment with the VIASKIN peanut patch, containing 250 micrograms of peanut protein (VP250) for 36 months, led to continued treatment response with a favorable safety profile over time. In this research, the PEOPLE end-of-study efficacy results from children who completed 60 months of active treatment were examined to determine the long-term efficacy of the peanut patch.
 
In PEPITES, peanut-allergic children from the ages 4 to 11 years old were randomized to either a placebo group or the VP250 group for 12 months. Upon completion, eligible participants enrolled in the extension study to receive open-label VP250 treatment for up to a total of 60 months to determine the percentage of treatment responders (per PEPITES criteria), eliciting dose and trends in peanut-specific immunoglobulin E (IgE) and immunoglobulin G4 (IgG4).
 
Of the 356 PEPITES participants, 298 enrolled in PEOPLE and 87 participants, 29.2%, continued treatment through month 60. The mean age range at the extension entry was 11.1 years of age. Among participants, the percentage of treatment responders increased from 39.1% at PEPITES completion to 52.9% at month 36 and then to 73.3% at month 60. Similarly, participants achieving an eliciting dose of more than 1000 mg increased from 33.3% at PEPITES completion to 48.3% by month 36 and to 66.7% at month 60. Median peanut-specific IgE and IgG4 levels both decreased and increased, respectively, from the previous baseline, which is consistent with other VIASKIN and allergen immunotherapy studies. The research determined that treatment compliance remained high with 93% of participants out to 5 years.

This data suggests that long-term VP250 peanut treatment patch in children with peanut allergies may lead to an accumulation of clinical benefit with high treatment compliance, making this a valuable option for children with allergies.
 
Visit aaaai.org to learn more about peanut allergies. Research presented at the 2025 AAAAI / WAO Joint Congress, February 28 – March 3 in San Diego, CA, is published in an online supplement to The Journal of Allergy and Clinical Immunology (JACI).

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists and other professionals with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders.